301211 亨迪药业
已收盘 04-02 15:00:00
资讯
新帖
简况
亨迪药业(301211.SZ)发布2025年度业绩,归母净利润3491.06万元,下降61.87%
智通财经网 · 03-30
亨迪药业(301211.SZ)发布2025年度业绩,归母净利润3491.06万元,下降61.87%
亨迪药业:截至2026年3月20日,公司股东户数为20,155户
证券之星 · 03-25
亨迪药业:截至2026年3月20日,公司股东户数为20,155户
亨迪药业:截至2026年3月10日,公司股东户数为20,200户
证券之星 · 03-16
亨迪药业:截至2026年3月10日,公司股东户数为20,200户
亨迪药业:截至2026年2月27日,公司股东户数为20,384户
证券之星 · 03-04
亨迪药业:截至2026年2月27日,公司股东户数为20,384户
亨迪药业:截至2026年2月13日,公司股东户数为20,757户
证券之星 · 02-24
亨迪药业:截至2026年2月13日,公司股东户数为20,757户
亨迪药业:截至2026年2月10日,公司股东户数为20,983户
证券之星 · 02-13
亨迪药业:截至2026年2月10日,公司股东户数为20,983户
亨迪药业(301211.SZ):盐酸埃克替尼化学原料药上市申请获批准
智通财经 · 02-03
亨迪药业(301211.SZ):盐酸埃克替尼化学原料药上市申请获批准
亨迪药业:截至2026年1月30日,公司股东户数为21,284户
证券之星 · 02-03
亨迪药业:截至2026年1月30日,公司股东户数为21,284户
亨迪药业最新公告:通过美国FDA现场检查
证券之星 · 01-26
亨迪药业最新公告:通过美国FDA现场检查
股市必读:亨迪药业(301211)股东户数2.09万户,较上期减少0.89%
证券之星 · 01-26
股市必读:亨迪药业(301211)股东户数2.09万户,较上期减少0.89%
亨迪药业:截至2026年1月20日股东户数为20,879户
证券之星 · 01-23
亨迪药业:截至2026年1月20日股东户数为20,879户
亨迪药业困在周期里?未走出单一业务依赖困局 股东组团减持失去信心?
新浪证券 · 01-16
亨迪药业困在周期里?未走出单一业务依赖困局 股东组团减持失去信心?
亨迪药业(301211)1月9日股东户数2.11万户,较上期增加2.27%
证券之星 · 01-14
亨迪药业(301211)1月9日股东户数2.11万户,较上期增加2.27%
亨迪药业最新公告:2025年净利同比预降57.40%-66.14%
证券之星 · 01-13
亨迪药业最新公告:2025年净利同比预降57.40%-66.14%
亨迪药业:截至2025年12月31日股东户数为20,598户
证券之星 · 01-06
亨迪药业:截至2025年12月31日股东户数为20,598户
亨迪药业(301211)12月19日股东户数2.14万户,较上期减少3.15%
证券之星 · 2025-12-25
亨迪药业(301211)12月19日股东户数2.14万户,较上期减少3.15%
亨迪药业:截至2025年12月19日股东户数为21,381户
证券之星 · 2025-12-23
亨迪药业:截至2025年12月19日股东户数为21,381户
亨迪药业:截至2025年12月10日股东户数为22,076户
证券之星 · 2025-12-15
亨迪药业:截至2025年12月10日股东户数为22,076户
亨迪药业:截至2025年11月28日股东户数为24,155户
证券之星 · 2025-12-02
亨迪药业:截至2025年11月28日股东户数为24,155户
亨迪药业:截至2025年11月20日股东户数为21,329户
证券之星 · 2025-11-24
亨迪药业:截至2025年11月20日股东户数为21,329户
加载更多
公司概况
公司名称:
湖北亨迪药业股份有限公司
所属行业:
医药制造业
上市日期:
2021-12-22
主营业务:
湖北亨迪药业股份有限公司的主营业务是化学原料药(含中间体)及制剂产品的研发、生产和销售,根据客户需求提供合同研发生产服务(CDMO)。公司的主要产品是布洛芬、右旋布洛芬、托拉塞米、米力农、醋酸阿比特龙、磷酸氟达拉滨、盐酸格拉司琼、克拉屈滨、硫酸莨菪碱、硫酸阿托品、布洛芬颗粒、布洛芬片、布洛芬缓释胶囊、布洛芬混悬液、布洛伪麻片、奥沙普秦肠溶片、奥沙普秦肠溶胶囊、托拉塞米片、托拉塞米注射剂、巴柳氮钠颗粒、多维元素片。公司是湖北省高新技术企业,公司历年来注重新技术、新工艺和新产品研发,先后承担了多项省级科研项目,相关产品多次荣获湖北省科技进步奖等。
发行价格:
25.80
{"stockData":{"symbol":"301211","market":"SZ","secType":"STK","nameCN":"亨迪药业","latestPrice":12.46,"timestamp":1775113398000,"preClose":12.34,"halted":0,"volume":7912641,"delay":0,"changeRate":0.0097,"floatShares":418000000,"shares":418000000,"eps":-0.0521,"marketStatus":"已收盘","change":0.12,"latestTime":"04-02 15:00:00","open":12.3,"high":12.6,"low":12.21,"amount":98605900,"amplitude":0.0316,"askPrice":12.46,"askSize":277,"bidPrice":12.45,"bidSize":64,"shortable":0,"etf":0,"ttmEps":-0.0521,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775179800000},"marketStatusCode":5,"adr":0,"adjPreClose":12.34,"symbolType":"stock","openAndCloseTimeList":[[1775093400000,1775100600000],[1775106000000,1775113200000]],"highLimit":13.57,"lowLimit":11.11,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":417600000,"isCdr":false,"pbRate":2.27,"roa":"--","roe":"1.53%","epsLYR":0.08,"committee":-0.490196,"marketValue":5203000000,"turnoverRate":0.0189,"status":0,"floatMarketCap":5203000000},"requestUrl":"/m/hq/s/301211","defaultTab":"news","newsList":[{"id":"2623339759","title":"亨迪药业(301211.SZ)发布2025年度业绩,归母净利润3491.06万元,下降61.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623339759","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623339759?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:14","pubTimestamp":1774858465,"startTime":"0","endTime":"0","summary":"亨迪药业(301211.SZ)发布2025年年度报告,该公司营业收入为4.53亿元,同比增长1.67%。归属于上市公司股东的净利润为3491.06万元,同比减少61.87%。归属于上市公司股东的扣除非经常性损益的净利润为788.35万元,同比减少89.19%。基本每股收益为0.08元。此外,拟向全体股东每10股派发现金红利0.6元(含税)。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622040350","title":"亨迪药业:截至2026年3月20日,公司股东户数为20,155户","url":"https://stock-news.laohu8.com/highlight/detail?id=2622040350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622040350?lang=zh_cn&edition=full","pubTime":"2026-03-25 15:00","pubTimestamp":1774422054,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,您好!敬请发布截至3月20日公司的股东户数信息,谢谢!亨迪药业回复:感谢您对公司的关注,截至2026年3月20日,公司股东户数为20,155户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500023412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619322324","title":"亨迪药业:截至2026年3月10日,公司股东户数为20,200户","url":"https://stock-news.laohu8.com/highlight/detail?id=2619322324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619322324?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:07","pubTimestamp":1773644837,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止3月10号,公司的股东人数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2026年3月10日,公司股东户数为20,200户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600014272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616538347","title":"亨迪药业:截至2026年2月27日,公司股东户数为20,384户","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538347?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:45","pubTimestamp":1772613920,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2月底的股东人数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2026年2月27日,公司股东户数为20,384户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400028709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613965127","title":"亨迪药业:截至2026年2月13日,公司股东户数为20,757户","url":"https://stock-news.laohu8.com/highlight/detail?id=2613965127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613965127?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:48","pubTimestamp":1771922887,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)02月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问最新一期公司的股东人数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2026年2月13日,公司股东户数为20,757户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400030877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611185066","title":"亨迪药业:截至2026年2月10日,公司股东户数为20,983户","url":"https://stock-news.laohu8.com/highlight/detail?id=2611185066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611185066?lang=zh_cn&edition=full","pubTime":"2026-02-13 11:36","pubTimestamp":1770953780,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)02月13日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问截止至2026年2月10日收盘公司股东人数为多少,谢谢!亨迪药业回复:感谢您对公司的关注,截至2026年2月10日,公司股东户数为20,983户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300014977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608282358","title":"亨迪药业(301211.SZ):盐酸埃克替尼化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608282358","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608282358?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:55","pubTimestamp":1770105316,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亨迪药业(301211.SZ)公告,公司近日收到国家药品监督管理局核准签发的关于盐酸埃克替尼的《化学原料药上市申请批准通知书》。据悉,盐酸埃克替尼是 EGFR酪氨酸激酶抑制剂类靶向药,主要用于治疗表皮生长因子受体(EGFR)基因存在敏感突变的局部晚期或转移性非小细胞肺癌,也可用于既往化疗失败的晚期非小细胞肺癌患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亨迪药业(301211.SZ):盐酸埃克替尼化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608814701","title":"亨迪药业:截至2026年1月30日,公司股东户数为21,284户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608814701","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608814701?lang=zh_cn&edition=full","pubTime":"2026-02-03 09:12","pubTimestamp":1770081128,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问1月31日公司股东人数是多少?谢谢!亨迪药业回复:感谢您对公司的关注,截至2026年1月30日,公司股东户数为21,284户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300008017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606164852","title":"亨迪药业最新公告:通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2606164852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606164852?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:09","pubTimestamp":1769422171,"startTime":"0","endTime":"0","summary":"亨迪药业(301211.SZ)公告称,公司于2025年11月10日至14日接受了美国FDA的CGMP日常监管现场检查,并收到了FDA出具的现场检查报告。FDA确认公司通过本次检查,检查结果为VAI(自愿采取整改)。这表明公司质量体系持续符合美国FDA要求,有助于提升公司国际市场竞争力和综合竞争力。但需注意国际原料药业务受海外市场环境等因素影响,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606779263","title":"股市必读:亨迪药业(301211)股东户数2.09万户,较上期减少0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606779263","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606779263?lang=zh_cn&edition=full","pubTime":"2026-01-26 02:37","pubTimestamp":1769366230,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,亨迪药业报收于12.97元,上涨1.49%,换手率1.49%,成交量6.21万手,成交额8019.87万元。股本股东变化股东户数变动近日亨迪药业披露,截至2026年1月20日公司股东户数为2.09万户,较1月9日减少187.0户,减幅为0.89%。户均持股数量由上期的1.98万股增加至2.0万股,户均持股市值为25.32万元。董秘最新回复投资者: 董秘您好,请问公司到1月20日的股东人数,谢谢董秘: 感谢您对公司的关注,截至2026年1月20日,公司股东户数为20,879户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605842896","title":"亨迪药业:截至2026年1月20日股东户数为20,879户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605842896","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605842896?lang=zh_cn&edition=full","pubTime":"2026-01-23 11:34","pubTimestamp":1769139267,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问公司到1月20日的股东人数,谢谢亨迪药业回复:感谢您对公司的关注,截至2026年1月20日,公司股东户数为20,879户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300015650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603159962","title":"亨迪药业困在周期里?未走出单一业务依赖困局 股东组团减持失去信心?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603159962","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603159962?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:22","pubTimestamp":1768558920,"startTime":"0","endTime":"0","summary":" 核心观点:亨迪药业2025年业绩预警,核心利润暴跌超九成,凸显其深陷布洛芬原料药“单一依赖” 困境。业绩下滑主因是全球布洛芬市场供需失衡、价格持续低迷,导致公司毛利率大幅收缩。公司已终止5000吨扩产计划,转向制剂与CDMO业务寻求转型,但新业务短期内难挑大梁,同时公司主要股东“组团”减持,是否进一步反映出市场对其短期破局信心不足? 近日,亨迪药业发布2025年业绩预告,业绩降至盈亏平衡线。 困在周期里?","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-01-16/doc-inhhnzaw0679320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603699729","title":"亨迪药业(301211)1月9日股东户数2.11万户,较上期增加2.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699729","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699729?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:28","pubTimestamp":1768382918,"startTime":"0","endTime":"0","summary":"证券之星消息,近日亨迪药业披露,截至2026年1月9日公司股东户数为2.11万户,较12月31日增加468.0户,增幅为2.27%。在化学制药行业个股中,亨迪药业股东户数低于行业平均水平,截至1月9日,化学制药行业平均股东户数为3.43万户。从股价来看,2025年12月31日至2026年1月9日,亨迪药业区间涨幅为5.65%,在此期间股东户数增加468.0户,增幅为2.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603760504","title":"亨迪药业最新公告:2025年净利同比预降57.40%-66.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603760504","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603760504?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:26","pubTimestamp":1768296384,"startTime":"0","endTime":"0","summary":"亨迪药业(301211.SZ)公告称,亨迪药业发布2025年度业绩预告,预计归属于上市公司股东的净利润为3,100万元-3,900万元,比上年同期下降57.40%-66.14%。基本每股收益为0.13元/股-0.16元/股。报告期内,主产品布洛芬原料药及部分特色原料药产品市场竞争加剧导致毛利率下降,同时现金管理利息收入因利率下行减少,致使公司盈利同比明显下滑。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300028970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601504138","title":"亨迪药业:截至2025年12月31日股东户数为20,598户","url":"https://stock-news.laohu8.com/highlight/detail?id=2601504138","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601504138?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:33","pubTimestamp":1767670406,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,您好!请问公司截至12月31日的股东人数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2025年12月31日,公司股东户数为20,598户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600015660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594236881","title":"亨迪药业(301211)12月19日股东户数2.14万户,较上期减少3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236881","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594236881?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:43","pubTimestamp":1766655808,"startTime":"0","endTime":"0","summary":"证券之星消息,近日亨迪药业披露,截至2025年12月19日公司股东户数为2.14万户,较12月10日减少695.0户,减幅为3.15%。在化学制药行业个股中,亨迪药业股东户数低于行业平均水平,截至12月19日,化学制药行业平均股东户数为3.46万户。从股价来看,2025年12月10日至2025年12月19日,亨迪药业区间跌幅为5.04%,在此期间股东户数减少695.0户,减幅为3.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500026550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593451047","title":"亨迪药业:截至2025年12月19日股东户数为21,381户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593451047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593451047?lang=zh_cn&edition=full","pubTime":"2025-12-23 08:42","pubTimestamp":1766450542,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年12月20日公司的股东总数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2025年12月19日,公司股东户数为21,381户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300006119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591619128","title":"亨迪药业:截至2025年12月10日股东户数为22,076户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591619128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591619128?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787453,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2025年12月10日股东人数是多少?亨迪药业回复:感谢您对公司的关注,截至2025年12月10日,公司股东户数为22,076户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500017439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588870285","title":"亨迪药业:截至2025年11月28日股东户数为24,155户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588870285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588870285?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:42","pubTimestamp":1764636132,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,您好!请问公司截至11月30日的股东人数是多少?谢谢亨迪药业回复:感谢您对公司的关注,截至2025年11月28日,公司股东户数为24,155户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585437444","title":"亨迪药业:截至2025年11月20日股东户数为21,329户","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585437444?lang=zh_cn&edition=full","pubTime":"2025-11-24 11:36","pubTimestamp":1763955382,"startTime":"0","endTime":"0","summary":"证券之星消息,亨迪药业(301211)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,作为贵公司的中小股投资者,截止11月20日的股东人数是多少人,谢谢!亨迪药业回复:感谢您对公司的关注,截至2025年11月20日,公司股东户数为21,329户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400008958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775126205147,"stockEarnings":[{"period":"1week","weight":0.052},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.0344},{"period":"1year","weight":-0.0458},{"period":"ytd","weight":0.0098}],"compareEarnings":[{"period":"1week","weight":0.0043},{"period":"1month","weight":-0.056},{"period":"3month","weight":-0.0051},{"period":"6month","weight":0.0169},{"period":"1year","weight":0.1792},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北亨迪药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20155人(较上一季度减少0.22%)","perCapita":"20719股","listingDate":"2021-12-22","address":"湖北省荆门市掇刀区杨湾路122号","registeredCapital":"41760万元","survey":" 湖北亨迪药业股份有限公司的主营业务是化学原料药(含中间体)及制剂产品的研发、生产和销售,根据客户需求提供合同研发生产服务(CDMO)。公司的主要产品是布洛芬、右旋布洛芬、托拉塞米、米力农、醋酸阿比特龙、磷酸氟达拉滨、盐酸格拉司琼、克拉屈滨、硫酸莨菪碱、硫酸阿托品、布洛芬颗粒、布洛芬片、布洛芬缓释胶囊、布洛芬混悬液、布洛伪麻片、奥沙普秦肠溶片、奥沙普秦肠溶胶囊、托拉塞米片、托拉塞米注射剂、巴柳氮钠颗粒、多维元素片。公司是湖北省高新技术企业,公司历年来注重新技术、新工艺和新产品研发,先后承担了多项省级科研项目,相关产品多次荣获湖北省科技进步奖等。","listedPrice":25.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亨迪药业(301211)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亨迪药业(301211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亨迪药业,301211,亨迪药业股票,亨迪药业股票老虎,亨迪药业股票老虎国际,亨迪药业行情,亨迪药业股票行情,亨迪药业股价,亨迪药业股市,亨迪药业股票价格,亨迪药业股票交易,亨迪药业股票购买,亨迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亨迪药业(301211)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亨迪药业(301211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}